Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.

Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials

Open access
Kryst, Joanna, Kawalec, Paweł, Mitoraj, Alicja Mikrut, Pilc, Andrzej, Lasoń, Władysław, Brzostek, Tomasz · 2020 · Pharmacological Reports

Abstract

Background: Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains. Methods: Electronic databases (Medline via PubMed, Embase, Cochrane Library, Trip Database) were systematically searched until February 22, 2019, for published peer-reviewed randomized controlled trials (RCTs) concerning a single and repeated administration of ketamine in patients with major depression. All relevant RCTs were selected and critically appraised, and a meta-analysis of eligible studies was performed. Results: A total of 20 studies were included in the meta-analysis. The largest effect of ketamine vs. controls in reducing depressive symptoms was observed at 24 h (SMD = − 0.89; 95% CI − 1.24; − 0.53; p < 0.00001); however, a significant difference was shown for up to 7 days after a single dose. Significant differences compared with controls were observed for up to 7 days in treatment-resistant patients and when ketamine was added to ongoing antidepressant treatment, while there were no significant differences at 7 days when ketamine was used as monotherapy. In patients with major depression, initial antidepressant effects of ketamine were maintained during repeated dosing. At 2–3 weeks of repeated ketamine treatment, significant reduction of depression severity scores was observed: SMD = − 0.70; 95% CI − 1.15; − 0.25 or SMD = − 0.81; 95% CI − 1.41; − 0.20 (depending on the dosing regimen used); p ≤ 0.009 vs placebo. Conclusions: Our meta-analysis revealed rapid and robust antidepressant effects of single-dose ketamine in patients with treatment-resistant depression (TRD). By pooling data from RCTs, we showed for the first time that repeated ketamine administration is effective in sustaining initial antidepressant effects observed after single dosing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43440-020-00097-z

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flow diagram for selection of studies identified in the systematic review
Fig. 1 PRISMA flow diagram for selection of studies identified in the systematic reviewCC BY · PubMed Central
Fig. 2 Risk of bias summary: review authors’ judgements about each risk of bias item for each included study
Fig. 2 Risk of bias summary: review authors’ judgements about each risk of bias item for each included studyCC BY · PubMed Central
Fig. 3 Effects of single-dose ketamine on depression rating scale at 24 h, 3–4 days, and 7 days
Fig. 3 Effects of single-dose ketamine on depression rating scale at 24 h, 3–4 days, and 7 daysCC BY · PubMed Central
Fig. 4 Effects of single-dose ketamine on response rates at 24 h (sensitivity analysis after exclusion of the study by Grunebaum et al. [29]), 3–4 days, and 7 days
Fig. 4 Effects of single-dose ketamine on response rates at 24 h (sensitivity analysis after exclusion of the study by Grunebaum et al. [29]), 3–4 days, and 7 daysCC BY · PubMed Central
Fig. 5 Effects of single-dose ketamine on remission rates at 24 h, 3–4 days, and 7 days
Fig. 5 Effects of single-dose ketamine on remission rates at 24 h, 3–4 days, and 7 daysCC BY · PubMed Central
Fig. 6 Meta-analysis results: time course of overall standardized mean differences (SMD) between ketamine and control in major depression—a subgroup analysis (abbreviations, see Table 2)
Fig. 6 Meta-analysis results: time course of overall standardized mean differences (SMD) between ketamine and control in major depression—a subgroup analysis (abbreviations, see Table 2)CC BY · PubMed Central
Fig. 7 Effects of serial ketamine on depression rating scale at 2–3 weeks; data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study by Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
Fig. 7 Effects of serial ketamine on depression rating scale at 2–3 weeks; data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study by Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]CC BY · PubMed Central
Fig. 8 Effects of serial ketamine on response at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
Fig. 8 Effects of serial ketamine on response at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]CC BY · PubMed Central
Fig. 9 Effects of serial ketamine on remission at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
Fig. 9 Effects of serial ketamine on remission at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 159

Metadata

Authors
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T.
Affiliations
  • Maj Institute of Pharmacology (PL)
  • Jagiellonian University (PL)
Corresponding author
Pilc, Andrzej
Venue
Pharmacological Reports
Published
2020-04-16
Volume
72
Issue
3
Pages
543-562
ISSN
  • 1734-1140 (ISSN-L)
  • 2299-5684
OpenAlex
W3016734864
Cited by
159
References
74
Citations by year
2026: 24 · 2025: 28 · 2024: 22 · 2023: 23 · 2022: 31 · 2021: 26 · 2020: 5
FWCI
2.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, major depressive disorder, treatment-resistant depression, bipolar depression, rapid antidepressant effects, adjunctive antidepressant therapy, monotherapy
MeSH terms
Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Ketamine, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1007/s43440-020-00097-z
The paper
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020). Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacological Reports. https://doi.org/10.1007/s43440-020-00097-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.